How to Read and Trade AI Powered Stock Charts
Enter Stock Symbol to View AI powered Stock Chart
StockChartsAI.com
All Chart Prices as of Previous Day CloseBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
12/07/2023 16:13:00 EST
10X Genomics Inc (TXG)
Industry: Health Information Services
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 30 trading days, TXG has been trading in a range between $43.42 and $34.32 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
TXG is trading between resistance at $51.36 about 8% to the upside and support at $41.85 -12% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $54.70, about a 15% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
10X Genomics Inc (TXG) entered a Green zone 16 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 4.000, which is a Buy. The current analyst target price is $60.33, which gives it a potential upside of 26.82 % from the recent price of 47.57. The stock is trading 33.63% (potential upside) below its 52 week high of $63.57 and 52.08 % (potential downside) above its 52 week low of $31.28 - based on the recent price.
Company Summary
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
News
| 10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research. Source: PRNewsWire Thu, 07 Dec 2023 09:00:00 -0500 Sentiment: Neutral |
| NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics. Source: GeekWire Mon, 20 Nov 2023 11:42:27 -0500 Sentiment: Negative |
| 10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (Nasdaq: NSTG). Source: PRNewsWire Fri, 17 Nov 2023 17:22:00 -0500 Sentiment: Neutral |
| OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery. Source: PRNewsWire Mon, 06 Nov 2023 16:05:00 -0500 Sentiment: Neutral |
| 10x Genomics: Unveiling The Investment Potential 10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap. Source: Seeking Alpha Sat, 04 Nov 2023 01:02:01 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 63.57 52 Week Low: 31.28 Beta: 1.878 50 Day MA: 40.1312 200 Day MA: 49.4251 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.172 Forward PE: 196.0784 Trailing PE: 0